Literature DB >> 29542002

Immunohistochemical Biomarkers of Adrenal Cortical Neoplasms.

Ozgur Mete1, Sylvia L Asa2, Thomas J Giordano3, Mauro Papotti4, Hironobu Sasano5, Marco Volante6.   

Abstract

Careful morphological evaluation forms the basis of the workup of an adrenal cortical neoplasm. However, the adoption of immunohistochemical biomarkers has added tremendous value to enhance diagnostic accuracy. The authors provide a brief review of immunohistochemical biomarkers that have been used in the confirmation of adrenal cortical origin and in the detection of the source of functional adrenal cortical proliferations, as well as diagnostic, predictive, and prognostic biomarkers of adrenal cortical carcinoma. In addition, a brief section on potential novel theranostic biomarkers in the prediction of treatment response to mitotane and other relevant chemotherapeutic agents is also provided. In the era of precision and personalized medical practice, adoption of combined morphology and immunohistochemistry provides a new approach to the diagnostic workup of adrenal cortical neoplasms, reflecting the evolution of clinical responsibility of pathologists.

Entities:  

Keywords:  Adrenal cortical carcinoma; Beta-catenin; CYP11B1; CYP11B2; IGF-2; Immunohistochemistry; Ki67; Mitotane; SF-1; p53

Mesh:

Substances:

Year:  2018        PMID: 29542002     DOI: 10.1007/s12022-018-9525-8

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  105 in total

1.  Inhibition of centrosome separation after DNA damage: a role for Nek2.

Authors:  Lynda Fletcher; George J Cerniglia; Erich A Nigg; Tim J Yend; Ruth J Muschel
Journal:  Radiat Res       Date:  2004-08       Impact factor: 2.841

2.  RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization.

Authors:  Antonina Germano; Ida Rapa; Marco Volante; Silvia De Francia; Cristina Migliore; Alfredo Berruti; Mauro Papotti; Massimo Terzolo
Journal:  Mol Cell Endocrinol       Date:  2014-12-09       Impact factor: 4.102

3.  Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and β-catenin.

Authors:  Joanne H Heaton; Michelle A Wood; Alex C Kim; Lorena O Lima; Ferdous M Barlaskar; Madson Q Almeida; Maria C B V Fragoso; Rork Kuick; Antonio M Lerario; Derek P Simon; Ibere C Soares; Elisabeth Starnes; Dafydd G Thomas; Ana C Latronico; Thomas J Giordano; Gary D Hammer
Journal:  Am J Pathol       Date:  2012-07-15       Impact factor: 4.307

4.  Xp11 Translocation Renal Cell Carcinomas (RCCs) With RBM10-TFE3 Gene Fusion Demonstrating Melanotic Features and Overlapping Morphology With t(6;11) RCC: Interest and Diagnostic Pitfall in Detecting a Paracentric Inversion of TFE3.

Authors:  Qiu-Yuan Xia; Xiao-Tong Wang; Xue-Mei Zhan; Xiao Tan; Hao Chen; Yi Liu; Shan-Shan Shi; Xuan Wang; Xue Wei; Sheng-Bing Ye; Rui Li; Heng-Hui Ma; Zhen-Feng Lu; Xiao-Jun Zhou; Qiu Rao
Journal:  Am J Surg Pathol       Date:  2017-05       Impact factor: 6.394

5.  Pathologic features and expression of insulin-like growth factor-2 in adrenocortical neoplasms.

Authors:  L A Erickson; L Jin; T J Sebo; C Lohse; V S Pankratz; M L Kendrick; J A van Heerden; G B Thompson; C S Grant; R V Lloyd
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

6.  Comparative diagnostic and prognostic performances of the hematoxylin-eosin and phospho-histone H3 mitotic count and Ki-67 index in adrenocortical carcinoma.

Authors:  Eleonora Duregon; Luca Molinaro; Marco Volante; Laura Ventura; Luisella Righi; Stefania Bolla; Massimo Terzolo; Anna Sapino; Mauro G Papotti
Journal:  Mod Pathol       Date:  2014-01-17       Impact factor: 7.842

7.  Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents.

Authors:  Paolo Mulatero; Michael Stowasser; Keh-Chuan Loh; Carlos E Fardella; Richard D Gordon; Lorena Mosso; Celso E Gomez-Sanchez; Franco Veglio; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2004-03       Impact factor: 5.958

8.  p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies.

Authors:  M Reincke; M Karl; W H Travis; G Mastorakos; B Allolio; H M Linehan; G P Chrousos
Journal:  J Clin Endocrinol Metab       Date:  1994-03       Impact factor: 5.958

9.  The emerging role of the molecular marker p27 in the differential diagnosis of adrenocortical tumors.

Authors:  Sofia S Pereira; Tiago Morais; Madalena M Costa; Mariana P Monteiro; Duarte Pignatelli
Journal:  Endocr Connect       Date:  2013-08-28       Impact factor: 3.335

10.  Distinguishing adrenal cortical carcinomas and adenomas: a study of clinicopathological features and biomarkers.

Authors:  Cuiping Wang; Yang Sun; Huanwen Wu; Dachun Zhao; Jie Chen
Journal:  Histopathology       Date:  2013-11-23       Impact factor: 5.087

View more
  9 in total

1.  Editorial: Special Issue on Immunohistochemical Biomarkers in Endocrine Pathology.

Authors:  Lori A Erickson; Ozgur Mete
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

Review 2.  What Did We Learn from the Molecular Biology of Adrenal Cortical Neoplasia? From Histopathology to Translational Genomics.

Authors:  C Christofer Juhlin; Ozgur Mete; Jérôme Bertherat; Thomas J Giordano; Gary D Hammer; Hironobu Sasano
Journal:  Endocr Pathol       Date:  2021-02-03       Impact factor: 3.943

3.  H-score of 11β-hydroxylase and aldosterone synthase in the histopathological diagnosis of adrenocortical tumors.

Authors:  Yi Yang; Ming Xiao; Ying Song; Yi Tang; Ting Luo; Shumin Yang; Wenwen He; Qingfeng Cheng; Linqiang Ma; Yao Zhang; Yunfeng He; Youde Cao; Jun Yang; Bin Peng; Jinbo Hu; Qifu Li
Journal:  Endocrine       Date:  2019-07-22       Impact factor: 3.633

Review 4.  Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.

Authors:  Ozgur Mete; Sylvia L Asa; Anthony J Gill; Noriko Kimura; Ronald R de Krijger; Arthur Tischler
Journal:  Endocr Pathol       Date:  2022-03-13       Impact factor: 3.943

5.  Low Protein Expression of both ATRX and ZNRF3 as Novel Negative Prognostic Markers of Adult Adrenocortical Carcinoma.

Authors:  Vania Balderrama Brondani; Amanda Meneses Ferreira Lacombe; Beatriz Marinho de Paula Mariani; Luciana Montenegro; Iberê Cauduro Soares; João Evangelista Bezerra-Neto; Fabio Yoshiaki Tanno; Victor Srougi; José Luis Chambo; Berenice Bilharinho Mendonca; Madson Q Almeida; Maria Claudia Nogueira Zerbini; Maria Candida Barisson Villares Fragoso
Journal:  Int J Mol Sci       Date:  2021-01-27       Impact factor: 5.923

6.  Differentiating Benign from Malignant Adrenocortical Tumors by a Single Morphological Parameter-a Clinicopathological Study on 837 Adrenocortical Neoplasias.

Authors:  Martin K Walz; Klaus A Metz; Sarah Theurer; Cathrin Myland; Pier F Alesina; Kurt W Schmid
Journal:  Indian J Surg Oncol       Date:  2020-09-05

Review 7.  Overview of the 2022 WHO Classification of Adrenal Cortical Tumors.

Authors:  Ozgur Mete; Lori A Erickson; C Christofer Juhlin; Ronald R de Krijger; Hironobu Sasano; Marco Volante; Mauro G Papotti
Journal:  Endocr Pathol       Date:  2022-03-14       Impact factor: 4.056

8.  The Role of Immunohistochemical Markers for the Diagnosis and Prognosis of Adrenocortical Neoplasms.

Authors:  Anna Angelousi; Georgios Kyriakopoulos; Fani Athanasouli; Anastasia Dimitriadi; Eva Kassi; Chrysanthi Aggeli; George Zografos; Gregory Kaltsas
Journal:  J Pers Med       Date:  2021-03-15

9.  Long-chain noncoding RNA-GAS5/hsa-miR-138-5p attenuates high glucose-induced cardiomyocyte damage by targeting CYP11B2.

Authors:  Xiaozhen Zhuo; Kai Bai; Yingxian Wang; Peining Liu; Wen Xi; Jianqing She; Junhui Liu
Journal:  Biosci Rep       Date:  2021-09-30       Impact factor: 3.840

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.